These latest data sets, which evaluated the system across a wide range of users, including historically challenging younger patients, those not meeting gly...
he goal of the collaboration is to reduce the time and resources it takes to translate a biomedical breakthrough into a clinically and commercially viable ...
ADME studies are vital components of drug development, providing critical insights into the behavior of drugs within the human body. By measuring the absor...
Biopharma’s own leaders express a declining sense of industry resilience in the latest wide-reaching survey from Cytiva. The Global Biopharma Resilie...
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that the U.S. Federal Bureau of Investigation (FBI) has approved its ForenSeq® Mains...
23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today released a new report as part of the 23andMe+ sub...
“This expansion of our relationship with Illumina is a continuation of Illumina Ventures’ strategy to pursue earlier stage investing,” sa...
Prior to joining Catalent, Mr. Masanovich served as Executive Vice President & Chief Financial Officer of Tenneco Automotive until it was acquired by A...
U.S. Food and Drug Administration announced a new voluntary pilot program for certain oncology drug products used with certain corresponding in vitro diagn...
Shawn Kumar, Founder and CEO of RhythmScience, expressed his excitement about the partnership, stating, "We are thrilled to partner with MedAxiom, the epit...
Deloitte is proud to announce the launch of "Illustrate Change," a project that seeks to build momentum around representation in medical illustrations and ...
"Compared to adults, children with type 2 diabetes have limited treatment options, even though the disease and symptom onset generally progress more rapidl...
Joining ReMY on the round were new investors Boro Capital, Supernode Ventures, MedMountain Ventures, The Triangle Tweener Fund, David Golan, and Silic...
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with canc...
© 2025 Biopharma Boardroom. All Rights Reserved.
